Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Buys Cancer Dx Developer Catalyst Oncology for $3M Plus Milestone Payments

NEW YORK (GenomeWeb News) - DiagnoCure today it said has acquired Catalyst Oncology, a Worcester, Mass.-based maker of prognostic tests for breast and colon cancers, for $3 million in cash and stock and potential future payments based on specific milestones.
DiagnoCure plans to complete the development of Catalyst's tests and conduct additional clinical studies. The newly acquired tests have already been validated in “multiple clinical studies involving patients with five tumor types," including breast and colon, the company said.
The tests, which measure the level of activated tyrosine phosphorylated Shc protein and p66 Shc protein in tissue specimens, have successfully indicated the risk of recurrence of cancer and have predicted the response to cancer therapies, including tamoxifen and traditional chemotherapy, DiagnoCure said.
DiagnoCure CEO John Schafer said in a statement that the company’s merger and acquisition strategy is "aimed at building a critical mass of high-value oncology diagnostic products” that will be offered through its CLIA-certified laboratory, which is expected to open later this year.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.